A legacy CE certificate can create a false sense of security. For many medical device manufacturers, the real EU MDR challenge is not whether a product may remain on the market for a transitional period. It is whether the organization can produce the technical, clinical, quality, and post-market evidence needed when its notified body asks for it.

This EU MDR transition guide is designed for device makers that need to protect European market access while building a practical route to MDR certification. The transition is a program-level business decision, not a documentation exercise. Product portfolio priorities, notified body capacity, clinical evidence gaps, QMS maturity, and certificate timing must be managed as one coordinated plan.

Start With the Actual Transition Conditions

EU MDR transitional provisions may allow certain legacy devices to remain available until December 31, 2027 or December 31, 2028, depending on device classification and other criteria. Higher-risk devices generally face the earlier deadline, while certain lower-risk devices may qualify for the later date. However, the applicable date is only one part of the analysis.

A device does not gain transition status simply because it was previously CE marked under the Medical Device Directive or Active Implantable Medical Devices Directive. Manufacturers must satisfy specific conditions, including continued compliance with the applicable legacy directive, no significant changes in design or intended purpose, and no unacceptable risk to patient health and safety. They must also have established an MDR-compliant quality management system by the required date and meet the relevant notified body application and written-agreement milestones.

Those conditions deserve formal ownership. A commercial team may see a transition extension as additional selling time. A regulatory leader should view it as a conditional runway that can disappear if evidence, agreements, surveillance obligations, or change control are not managed carefully.

Confirm Which Products Are Worth Transitioning

Not every legacy product should move through MDR certification. Some products have declining revenue, limited strategic value, or clinical evidence requirements that would be disproportionate to their expected return. Others are central to a platform strategy or important for maintaining customer relationships and should receive early investment.

A portfolio review should assess expected EU revenue, remaining certificate validity, MDR classification, notified body availability, clinical evidence readiness, quality system gaps, and planned product changes. The result should be a decision for each product or family: transition under MDR, remediate before submission, retire from the EU market, or replace with a next-generation product.

This is where trade-offs become visible. Retiring a low-volume device may reduce certification expense, but it may also affect tender eligibility, distributor commitments, or the perceived completeness of a broader product offering. Conversely, pursuing MDR certification for every product can consume resources better directed toward high-value devices.

Build the EU MDR Transition Plan Around Evidence

The MDR requires manufacturers to demonstrate conformity through a connected body of evidence. Technical documentation, clinical evaluation, risk management, usability, cybersecurity where applicable, post-market surveillance, and supplier controls cannot be prepared in isolation and expected to align at the end.

Begin with a structured MDR gap assessment against the device’s current state. The assessment should identify not only missing documents but also weak evidence chains. For example, a clinical evaluation may cite literature that does not adequately support the device’s intended purpose, target population, claims, or state of the art. A risk management file may exist, but it may not show clear linkage to post-market data, labeling, verification activities, and benefit-risk conclusions.

The right output is a prioritized remediation plan with named owners, realistic due dates, dependencies, and decision points. It should distinguish between work needed to preserve transition eligibility and work needed for a complete MDR submission. Both matter, but they may follow different timelines.

Clinical Evaluation Often Sets the Pace

For established devices, manufacturers sometimes assume that years of commercial history will substitute for a current clinical strategy. Real-world experience is valuable, but it must be collected, analyzed, and presented in a way that supports the device’s intended purpose and clinical claims.

The clinical evaluation should address equivalence carefully. Under MDR, demonstrating equivalence to another device can be difficult, particularly when the manufacturer lacks sufficient access to the comparator’s technical, biological, and clinical data. When equivalence is not defensible, the manufacturer may need to rely more heavily on its own clinical data, literature, post-market data, or a post-market clinical follow-up plan.

Whether a clinical investigation is necessary depends on the device, indication, risk profile, available evidence, and gaps identified by the notified body. The most efficient path is not always the path with the least data collection. A focused clinical strategy developed early can prevent repeated rounds of notified body questions and an avoidable loss of market access.

Treat the QMS as an Operating System

An MDR-compliant QMS must do more than contain updated procedures. It must show that the organization can consistently control the product throughout its lifecycle. Notified bodies will look for implementation evidence, including training records, management review outputs, supplier controls, complaint handling, vigilance processes, CAPA records, and internal audit results.

Particular attention should be given to post-market surveillance. The PMS plan, periodic safety update report or PMS report, trend reporting process, complaint data, and clinical follow-up activities should tell a coherent story. If complaints indicate a recurring failure mode, the risk file, clinical evaluation, labeling, CAPA process, and benefit-risk assessment may all require review.

For US-based companies, it is tempting to map existing FDA quality processes directly to MDR requirements. There is meaningful overlap, but the regulatory intent, document expectations, economic operator responsibilities, and post-market reporting framework differ. A crosswalk can be useful, but it should never replace an MDR-specific assessment.

Secure Notified Body Capacity Before the Schedule Becomes Critical

Notified body availability remains a major scheduling variable. Even when a manufacturer has completed much of its documentation, certificate timing depends on application acceptance, contract status, review queues, audit scheduling, and the quality of the submitted evidence.

Engage early and submit a complete, well-organized application package. Incomplete applications may create delays that are difficult to recover later, especially when multiple products are competing for the same internal subject matter experts. Manufacturers should also plan for questions and nonconformities rather than treating them as exceptions. Review cycles, corrective action development, and evidence generation require time.

The written agreement with a notified body is not merely an administrative milestone. It confirms that the manufacturer has entered the certification pathway and establishes expectations for assessment. Keep records of application dates, contractual documentation, correspondence, and the status of each product family in a controlled transition tracker.

Control Changes During the Transition Period

The prohibition on significant changes in design or intended purpose is one of the most consequential transition risks. Product teams may need to address component obsolescence, cybersecurity vulnerabilities, manufacturing transfers, labeling updates, software revisions, or market-driven feature requests. Each change must be evaluated through a documented process before implementation.

Not every change is automatically significant. The answer depends on the nature of the change, its impact on safety and performance, the intended purpose, risk controls, clinical evidence, and the applicable regulatory guidance. A disciplined change assessment process should involve regulatory, quality, engineering, clinical, and commercial stakeholders when needed.

Waiting until a change is ready for release is too late. Build regulatory review into product planning, supplier strategy, and software release governance. This protects transition status while helping the organization decide whether a proposed update belongs in the legacy device, the MDR submission, or a future product iteration.

Make Governance Visible to Leadership

MDR transition programs fail when they are treated as a regulatory department project with no executive oversight. Leadership needs a clear view of each device’s market-access risk, certification path, evidence gaps, budget, notified body status, and decision deadlines.

A concise monthly governance review can be effective when it focuses on exceptions: products at risk of missing a milestone, unresolved clinical questions, major QMS remediation items, potential significant changes, and decisions requiring investment or portfolio action. The goal is not more reporting. It is faster resolution of issues that could affect commercialization.

Experienced external support can be particularly valuable when internal teams are balancing US submissions, product development, and international expansion. Qualira helps med tech teams connect regulatory strategy, quality execution, and submission readiness so that MDR work supports commercial priorities rather than becoming a separate compliance track.

The strongest transition programs create more than a path through a deadline. They establish the evidence discipline, quality controls, and decision-making structure needed to keep a device on the European market long after its MDR certificate is issued.